Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8<sup>+</sup> T cellsKathryn M LaPorte, Thomas R. Malek|Journal for ImmunoTherapy of Cancer|2023Cited by 27